Arcus Biosciences Inc logo

RCUS - Arcus Biosciences Inc News Story

$34.25 -1.1  -3.1%

Last Trade - 25/02/21

Sector
Healthcare
Size
Mid Cap
Market Cap £1.62bn
Enterprise Value £1.07bn
Revenue £55.0m
Position in Universe 2072nd / 6713

BUZZ-Arcus Biosciences: Truist hikes PT on stellar data from cancer treatment trial

Fri 15th January, 2021 3:39pm
** Cancer drug developer Arcus Biosciences Inc's  RCUS.N 
early-stage data of pancreatic cancer treatment exceeded
expectations, says Truist analyst Robyn Karnauskas
    ** Truist raises PT to $70 from $45; adds data from study
further validates RCUS' combo strategy across different
indications
    ** RCUS said on Friday its combination therapy, AB680, to
treat pancreatic cancer showed 41% objective response rate in an
early-stage trial. Data from trial was from 17 patients
    ** With multiple catalysts in 2021, we see potential for
significant upside to stock - Robyn Karnauskas
    ** Adds data support Gilead Inc's  GILD.O  partnership
strategy
    ** RCUS and GILD entered into 10-year partnership to
co-develop and co-commercialize RCUS's pipeline in May 2020
 urn:newsml:reuters.com:*:nL4N2D92II
    ** 9 of 10 brokerages rate stock "buy" or higher, 1 "hold";
their median PT is $40
    ** Stock has more than tripled in last 12 months 

 (Reporting by Dania Nadeem in Bengaluru)
 ((Dania.Nadeem@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.